Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial.

MLA

Sylvie, Chevret, et al. “Which Severe COVID-19 Patients Could Benefit from High Dose Dexamethasone? A Bayesian Post-Hoc Reanalysis of the COVIDICUS Randomized Clinical Trial.” Annals of Intensive Care, vol. 13, no. 1, Aug. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13613-023-01168-z.

APA

Sylvie, C., Lila, B., Claire, D., Charles, B., Jean-François, T., the COVIDICUS RCT group, Beldjoudi, N., Chevret, S., Burdet, C., Alloux, C., Amerali, F., Andriss, B., Baghli, K., Brocvielle, H., Capelle, F., Chibane, I., Dalibey, S., Ettalhaoui, N., Lamri, S., & Maurer, Y. (2023). Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. Annals of Intensive Care, 13(1), 1–12. https://doi.org/10.1186/s13613-023-01168-z

Chicago

Sylvie, Chevret, Bouadma Lila, Dupuis Claire, Burdet Charles, Timsit Jean-François, the COVIDICUS RCT group, Naima Beldjoudi, et al. 2023. “Which Severe COVID-19 Patients Could Benefit from High Dose Dexamethasone? A Bayesian Post-Hoc Reanalysis of the COVIDICUS Randomized Clinical Trial.” Annals of Intensive Care 13 (1): 1–12. doi:10.1186/s13613-023-01168-z.